The groundbreaking approach of this peptide represents a significant advance in the handling of type 2 diabetes. Unlike existing drugs, tirzepatide impacts dual pathways – glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) – resulting in greater blood sugar regulation and potential weight loss. Scientists are